Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist that can be used in the treatment of type 2 diabetes mellitus (T2DM).

Glucagon receptor antagonists-4 is an selective antagonist of glucagon receptor.

GRA Ex-25 is an inhibitor of glucagon receptor, with IC50 of 56 and 55 nM for rat and human glucagon receptors, respectively.

Exendin Fragment 9-39 is an antagonist of glucagon-like peptide-1 (GLP-1) receptor, and also acts as an inhibitor of glucosedependent insulinotropic polypeptide (GIP)-receptor binding.

Teduglutide , an analog of glucagon-like peptide 2, improves intestinal rehabilitation by promoting mucosal growth and possibly by inhibiting gastric emptying and secretion, which in turn reduces intestinal losses and promotes intestinal absorption.

Ubiquitin Isopeptidase Inhibitor I, G5 is an apoptosome-independent caspase and apoptosis activator.

Glucagon is a peptide hormone, exhibits therapeutic potential for metabolic disease.

PF-06882961 is a potent and orally bioavailable GLP-1R agonist.

Semaglutide is an analog of human GLP-1 with long-acting effect over the other GLP-1Ras.

BETP is an agonist of glucagon-like peptide-1 (GLP-1) receptor, with EC50s of 0.66 and 0.755 μM for human and rat GLP-1 receptor, respectively.

Exendin-4 is a high affinity glucagon-like peptide 1 (GLP-1) receptor agonist (Kd = 136 pM) and originally isolated from Heloderma suspectum venom.